Drug Trial Radar · NCT01833741
A Study of LUMIGAN® RC in the Clinical Setting
Last checked: Nov 19, 2026Latest source record: Sep 26, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,137
Actual
Start
Dec 2009
Primary completion
Mar 2011
Study completion Mar 2011
Sponsor
- Lead sponsor
- AllerganAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Apr 17, 2013
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate bimatoprost 0.01% (LUMIGAN® RC) in patients with elevated intraocular pressure (IOP) due to primary open angle glaucoma (POAG) or ocular hypertension (OHT) in a clinical setting.
Conditions
- Glaucoma, Primary Open Angle
- Ocular Hypertension
Interventions
Bimatoprost 0.01%Drug
Bimatoprost 0.01% (LUMIGAN® RC) administered as one drop in the study eye(s) each evening for 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Treatment-Naive Patients With Ocular HyperemiaTime frame: Week 12
- Percentage of Previously Treated (Switched) Patients With Ocular HyperemiaTime frame: Week 12
- Percentage of Patients Treated With Adjunctive Therapy With Ocular HyperemiaTime frame: Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Barrie, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.